World Allergy Organization Journal最新文献_第3页

The exploration of immunological landscape and drug targets in chronic rhinosinusitis with nasal polyps 慢性鼻窦炎伴鼻息肉的免疫景观及药物靶点探讨

IF 4.3 2区医学 Q2 ALLERGY

World Allergy Organization Journal

Pub Date : 2025-12-15 DOI: 10.1016/j.waojou.2025.101140

Ruxiang Zhang PhD, Peipei Fu PhD, Hao Tian PhD

Background

Chronic rhinosinusitis with nasal polyps (CRSwNP) is a prevalent inflammatory disorder characterized by nasal obstruction and polyp formation. Despite its prevalence, the complex pathogenesis of CRSwNP remains not fully understood, hindering the development of effective treatments. This study aims to delineate the immunological landscape of CRSwNP by integrating single-cell RNA sequencing (scRNA-seq) and Mendelian randomization (MR) approaches.

Methods

We conducted a systematic MR analysis using summary statistics from genome-wide association studies (GWAS) and expression quantitative trait loci (eQTL) data. The identified genes were further scrutinized through scRNA-seq analysis of CRSwNP tissues to assess cell-specific expression patterns. Pathway enrichment and protein-protein interaction (PPI) network analyses were performed to explore the biological mechanisms underlying CRSwNP.

Results

The MR analysis identified several genes, including HLA-DRB1, HLA-DQA1, and HLA-DQB1, as significantly associated with CRSwNP. The scRNA-seq analysis validated these findings, revealing cell-specific enrichment in basal cells. Notably, these genes were found to be involved in immune cell recruitment and the reshaping of the immune microenvironment. Furthermore, the study highlighted the role of genes like TCF7L1, KANSL1-AS1, and POLR2J3, which showed contrasting expression patterns and potential regulatory roles in CRSwNP.

Conclusion

This integrative study provides novel insights into the molecular and cellular underpinnings of CRSwNP. The identified genes and their role in immunopathogenesis offer potential therapeutic targets and highlight the importance of cell-specific gene expression in disease mechanisms. The combination of MR with scRNA-seq represents a powerful approach to elucidate complex traits and may pave the way for precision medicine in CRSwNP management.

慢性鼻窦炎伴鼻息肉（CRSwNP）是一种以鼻塞和息肉形成为特征的常见炎症性疾病。尽管CRSwNP普遍存在，但其复杂的发病机制仍未完全了解，这阻碍了有效治疗方法的发展。本研究旨在通过整合单细胞RNA测序（scRNA-seq）和孟德尔随机化（MR）方法来描绘CRSwNP的免疫学景观。方法利用全基因组关联研究（GWAS）和表达数量性状位点（eQTL）数据的汇总统计数据进行系统的MR分析。通过CRSwNP组织的scRNA-seq分析进一步仔细检查鉴定的基因，以评估细胞特异性表达模式。通过通路富集和蛋白-蛋白相互作用（PPI）网络分析来探索CRSwNP的生物学机制。结果MR分析确定了几个基因，包括HLA-DRB1、HLA-DQA1和HLA-DQB1，与CRSwNP显著相关。scRNA-seq分析证实了这些发现，揭示了基底细胞中的细胞特异性富集。值得注意的是，这些基因被发现参与免疫细胞募集和免疫微环境的重塑。此外，该研究强调了TCF7L1、KANSL1-AS1和POLR2J3等基因在CRSwNP中的作用，这些基因在CRSwNP中表现出不同的表达模式和潜在的调节作用。这项综合研究为CRSwNP的分子和细胞基础提供了新的见解。已鉴定的基因及其在免疫发病机制中的作用提供了潜在的治疗靶点，并突出了细胞特异性基因表达在疾病机制中的重要性。MR与scRNA-seq的结合代表了一种阐明复杂性状的有力方法，并可能为CRSwNP管理的精准医学铺平道路。

{"title":"The exploration of immunological landscape and drug targets in chronic rhinosinusitis with nasal polyps","authors":"Ruxiang Zhang PhD, Peipei Fu PhD, Hao Tian PhD","doi":"10.1016/j.waojou.2025.101140","DOIUrl":"10.1016/j.waojou.2025.101140","url":null,"abstract":"<div><h3>Background</h3><div>Chronic rhinosinusitis with nasal polyps (CRSwNP) is a prevalent inflammatory disorder characterized by nasal obstruction and polyp formation. Despite its prevalence, the complex pathogenesis of CRSwNP remains not fully understood, hindering the development of effective treatments. This study aims to delineate the immunological landscape of CRSwNP by integrating single-cell RNA sequencing (scRNA-seq) and Mendelian randomization (MR) approaches.</div></div><div><h3>Methods</h3><div>We conducted a systematic MR analysis using summary statistics from genome-wide association studies (GWAS) and expression quantitative trait loci (eQTL) data. The identified genes were further scrutinized through scRNA-seq analysis of CRSwNP tissues to assess cell-specific expression patterns. Pathway enrichment and protein-protein interaction (PPI) network analyses were performed to explore the biological mechanisms underlying CRSwNP.</div></div><div><h3>Results</h3><div>The MR analysis identified several genes, including HLA-DRB1, HLA-DQA1, and HLA-DQB1, as significantly associated with CRSwNP. The scRNA-seq analysis validated these findings, revealing cell-specific enrichment in basal cells. Notably, these genes were found to be involved in immune cell recruitment and the reshaping of the immune microenvironment. Furthermore, the study highlighted the role of genes like TCF7L1, KANSL1-AS1, and POLR2J3, which showed contrasting expression patterns and potential regulatory roles in CRSwNP.</div></div><div><h3>Conclusion</h3><div>This integrative study provides novel insights into the molecular and cellular underpinnings of CRSwNP. The identified genes and their role in immunopathogenesis offer potential therapeutic targets and highlight the importance of cell-specific gene expression in disease mechanisms. The combination of MR with scRNA-seq represents a powerful approach to elucidate complex traits and may pave the way for precision medicine in CRSwNP management.</div></div>","PeriodicalId":54295,"journal":{"name":"World Allergy Organization Journal","volume":"19 1","pages":"Article 101140"},"PeriodicalIF":4.3,"publicationDate":"2025-12-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145750227","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Corrigendum to “Pollen exposures in pregnancy and early life are associated with childhood asthma incidence” [World Allergy Organ J 17 (2024) 1–6] “孕期和早期接触花粉与儿童哮喘发病率相关”[世界过敏器官J 17(2024) 1-6]的勘误表

IF 4.3 2区医学 Q2 ALLERGY

World Allergy Organization Journal

Pub Date : 2025-12-01 DOI: 10.1016/j.waojou.2025.101148

Rajesh Melaram , James Adefisoye , Donald E. Warden , Stephen Potter , Hasan Arshad , Hongmei Zhang

引用次数: 0

Off-label applications of omalizumab: Current insights and perspectives omalizumab的适应症外应用：当前的见解和观点

IF 4.3 2区医学 Q2 ALLERGY

World Allergy Organization Journal

Pub Date : 2025-12-01 DOI: 10.1016/j.waojou.2025.101156

Aleksandra Jaromin MD, Aleksandra Wardzyńska MD, PhD

Omalizumab is a humanized monoclonal antibody that binds free IgE. Consequently, it exhibits inhibitory properties against allergic cascades. Over the past 20 years, omalizumab has been in the market, and studies have shown its strong tolerability and safety profile. Since 2003 in the United States of America and 2005 in Europe, omalizumab has been available to patients as a therapeutic option. In Europe, it is registered for the treatment of allergic asthma, chronic spontaneous urticaria, and chronic sinusitis with polyps. In the United States, it has been registered for the treatment of allergic asthma, chronic spontaneous urticaria, and chronic food allergies in children over 1 year of age. With a universal target point for most allergic conditions, omalizumab has the potential to become the most versatile biological drug for allergologists. The literature describes numerous uses of omalizumab as an adjuvant or monotherapy for allergic conjunctivitis, systemic mastocytosis, food allergies, drug hypersensitivity, allergic bronchopulmonary aspergillosis, and allergen immunotherapy, among others. In the following publication, we will provide you with the current knowledge regarding the use of omalizumab in conditions other than those covered by the current product registration.

Omalizumab是一种结合游离IgE的人源化单克隆抗体。因此，它表现出对过敏级联反应的抑制特性。在过去的20年里，omalizumab已经进入市场，研究表明其具有很强的耐受性和安全性。自2003年在美国和2005年在欧洲，omalizumab已作为一种治疗选择提供给患者。在欧洲，它被注册用于治疗过敏性哮喘，慢性自发性荨麻疹和慢性鼻窦炎伴息肉。在美国，它已被注册用于治疗1岁以上儿童的过敏性哮喘、慢性自发性荨麻疹和慢性食物过敏。对于大多数过敏情况，omalizumab具有普遍的靶点，有可能成为过敏症学家最通用的生物药物。文献描述了omalizumab作为过敏性结膜炎、全身性肥大细胞增多症、食物过敏、药物过敏、过敏性支气管肺曲霉病和过敏原免疫治疗等的辅助或单一治疗的许多用途。在接下来的出版物中，我们将为您提供有关在当前产品注册所涵盖的条件之外使用omalizumab的当前知识。

{"title":"Off-label applications of omalizumab: Current insights and perspectives","authors":"Aleksandra Jaromin MD, Aleksandra Wardzyńska MD, PhD","doi":"10.1016/j.waojou.2025.101156","DOIUrl":"10.1016/j.waojou.2025.101156","url":null,"abstract":"<div><div>Omalizumab is a humanized monoclonal antibody that binds free IgE. Consequently, it exhibits inhibitory properties against allergic cascades. Over the past 20 years, omalizumab has been in the market, and studies have shown its strong tolerability and safety profile. Since 2003 in the United States of America and 2005 in Europe, omalizumab has been available to patients as a therapeutic option. In Europe, it is registered for the treatment of allergic asthma, chronic spontaneous urticaria, and chronic sinusitis with polyps. In the United States, it has been registered for the treatment of allergic asthma, chronic spontaneous urticaria, and chronic food allergies in children over 1 year of age. With a universal target point for most allergic conditions, omalizumab has the potential to become the most versatile biological drug for allergologists. The literature describes numerous uses of omalizumab as an adjuvant or monotherapy for allergic conjunctivitis, systemic mastocytosis, food allergies, drug hypersensitivity, allergic bronchopulmonary aspergillosis, and allergen immunotherapy, among others. In the following publication, we will provide you with the current knowledge regarding the use of omalizumab in conditions other than those covered by the current product registration.</div></div>","PeriodicalId":54295,"journal":{"name":"World Allergy Organization Journal","volume":"18 12","pages":"Article 101156"},"PeriodicalIF":4.3,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145736988","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Economic burden of asthma multimorbidity in Singapore: Shadow costs of steroid use 新加坡哮喘多病的经济负担：类固醇使用的影子成本

IF 4.3 2区医学 Q2 ALLERGY

World Allergy Organization Journal

Pub Date : 2025-12-01 DOI: 10.1016/j.waojou.2025.101146

Laura Huey Mien Lim MSc , Yah Ru Juang BSc , Sanjay H. Chotirmall MB BCh BAO FRCPI FCCP FRCP PhD , Kelvin Bryan Tan PhD , Mariko Siyue Koh MBBS MRCP , John A. Abisheganaden MBBS MRCP MMed FAMS FRCP , David B. Price FRCGP , Ming-Ju Tsai MD PhD , Mei Fong Liew MBBS MRCP MMed , Pei Yee Tiew MD PhD , Anthony Chau Ang Yii MB BChir MA MRCP , Wenjia Chen PhD

Background

In some countries including Singapore, biologic therapies are not routinely available. Instead, oral corticosteroid (OCS) is commonly used for severe asthma management, which could lead to substantial adverse health events.

Objective

To estimate the multimorbidity costs in asthma patients from a multi-ethnic Asian population.

Methods

We examined national health administrative data (2012–2019) from Singapore. Direct medical costs were summed from costs of hospitalisation, emergency department (ED), specialist care, and public primary care. Prescription data were not available but formed part of public primary care costs. We measured cost per patient-year (PY) in 2023 Singaporean dollars (SGD$1 = US$0.76 = ₤0.60 = €0.69). We performed propensity-score matching on asthma and non-asthma patients, and applied generalised linear models to estimate total and excess costs due to asthma, OCS-related comorbidities, and other comorbidity groups.

Results

We identified 19,979 paediatric and 48,237 adult asthma patients (48.2% males, 50.4% Chinese, 13.9% Indian, 26.8% Malay), and matched equal number of non-asthma patients. Paediatric and adult asthma patients respectively incurred $816.3/PY (95% CI: $803.0/PY-$829.5/PY) and $1855.9/PY (95% CI: $1845.0/PY-$1871.0/PY) in total costs. The average ($1610.9/PY [95% CI: $1599.5/PY-$1621.3/PY]) was thrice of non-asthma patients’ ($530.4/PY). Excess costs (mean = $927.2/PY) were driven by asthma ($403.0/PY), OCS-related comorbidities ($104.0/PY), other metabolic disease ($116.4/PY), circulatory diseases ($112.9/PY) and non-asthma respiratory conditions ($107.4/PY). All excess cost components increased steadily over the 8-year study period.

Conclusion

The burden of asthma multimorbidity in Singapore is severe, with a considerable fraction attributable to OCS-related comorbidities. Policies should aim to reduce excess OCS use and enhance integrated multimorbidity management.

在包括新加坡在内的一些国家，生物疗法并不是常规疗法。相反，口服皮质类固醇（OCS）通常用于严重哮喘治疗，这可能导致严重的不良健康事件。目的评估亚洲多种族人群哮喘患者的多病成本。方法我们查阅了新加坡2012-2019年的国家卫生行政数据。直接医疗费用从住院费用、急诊科费用、专科护理费用和公共初级保健费用中总结。没有处方数据，但构成了公共初级保健费用的一部分。我们以2023年新加坡元（SGD$1 = US$0.76 =£0.60 =€0.69）衡量每患者年（PY）的成本。我们对哮喘和非哮喘患者进行了倾向评分匹配，并应用广义线性模型来估计哮喘、ocs相关合并症和其他合并症组的总成本和超额成本。结果共发现19,979例儿童哮喘患者和48,237例成人哮喘患者（男性48.2%，华人50.4%，印度人13.9%，马来人26.8%），非哮喘患者数量相等。儿科和成人哮喘患者的总成本分别为816.3美元/日元（95% CI: 803.0美元/日元- 829.5美元/日元）和1855.9美元/日元（95% CI: 1845.0美元/日元- 1871.0美元/日元）。平均（$1610.9/PY [95% CI: $1599.5/PY-$1621.3/PY]）是非哮喘患者（$530.4/PY）的三倍。额外费用（平均= 927.2美元/PY）由哮喘（403.0美元/PY）、ocs相关合并症（104.0美元/PY）、其他代谢疾病（116.4美元/PY）、循环系统疾病（112.9美元/PY）和非哮喘呼吸系统疾病（107.4美元/PY）驱动。所有超额成本组成部分在8年的研究期间稳步增长。结论新加坡哮喘多病负担严重，其中相当一部分可归因于与ocs相关的合并症。政策应旨在减少OCS的过度使用，并加强综合多病管理。

{"title":"Economic burden of asthma multimorbidity in Singapore: Shadow costs of steroid use","authors":"Laura Huey Mien Lim MSc , Yah Ru Juang BSc , Sanjay H. Chotirmall MB BCh BAO FRCPI FCCP FRCP PhD , Kelvin Bryan Tan PhD , Mariko Siyue Koh MBBS MRCP , John A. Abisheganaden MBBS MRCP MMed FAMS FRCP , David B. Price FRCGP , Ming-Ju Tsai MD PhD , Mei Fong Liew MBBS MRCP MMed , Pei Yee Tiew MD PhD , Anthony Chau Ang Yii MB BChir MA MRCP , Wenjia Chen PhD","doi":"10.1016/j.waojou.2025.101146","DOIUrl":"10.1016/j.waojou.2025.101146","url":null,"abstract":"<div><h3>Background</h3><div>In some countries including Singapore, biologic therapies are not routinely available. Instead, oral corticosteroid (OCS) is commonly used for severe asthma management, which could lead to substantial adverse health events.</div></div><div><h3>Objective</h3><div>To estimate the multimorbidity costs in asthma patients from a multi-ethnic Asian population.</div></div><div><h3>Methods</h3><div>We examined national health administrative data (2012–2019) from Singapore. Direct medical costs were summed from costs of hospitalisation, emergency department (ED), specialist care, and public primary care. Prescription data were not available but formed part of public primary care costs. We measured cost per patient-year (PY) in 2023 Singaporean dollars (SGD$1 = US$0.76 = ₤0.60 = €0.69). We performed propensity-score matching on asthma and non-asthma patients, and applied generalised linear models to estimate total and excess costs due to asthma, OCS-related comorbidities, and other comorbidity groups.</div></div><div><h3>Results</h3><div>We identified 19,979 paediatric and 48,237 adult asthma patients (48.2% males, 50.4% Chinese, 13.9% Indian, 26.8% Malay), and matched equal number of non-asthma patients. Paediatric and adult asthma patients respectively incurred $816.3/PY (95% CI: $803.0/PY-$829.5/PY) and $1855.9/PY (95% CI: $1845.0/PY-$1871.0/PY) in total costs. The average ($1610.9/PY [95% CI: $1599.5/PY-$1621.3/PY]) was thrice of non-asthma patients’ ($530.4/PY). Excess costs (mean = $927.2/PY) were driven by asthma ($403.0/PY), OCS-related comorbidities ($104.0/PY), other metabolic disease ($116.4/PY), circulatory diseases ($112.9/PY) and non-asthma respiratory conditions ($107.4/PY). All excess cost components increased steadily over the 8-year study period.</div></div><div><h3>Conclusion</h3><div>The burden of asthma multimorbidity in Singapore is severe, with a considerable fraction attributable to OCS-related comorbidities. Policies should aim to reduce excess OCS use and enhance integrated multimorbidity management.</div></div>","PeriodicalId":54295,"journal":{"name":"World Allergy Organization Journal","volume":"18 12","pages":"Article 101146"},"PeriodicalIF":4.3,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145624794","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Benralizumab: Bringing winds of change to eosinophil-associated diseases Benralizumab：为嗜酸性粒细胞相关疾病带来变革之风

IF 4.3 2区医学 Q2 ALLERGY

World Allergy Organization Journal

Pub Date : 2025-12-01 DOI: 10.1016/j.waojou.2025.101153

Stephanie Korn MD, PhD , Eugene R. Bleecker MD , Arnaud Bourdin MD, PhD , Christopher McCrae PhD , Maria L. Jison MD , Andrew Menzies-Gow PhD, FRCP

The majority of patients with severe asthma have an eosinophilic phenotype. Interleukin-5 (IL-5) plays a key role in the pathophysiology of severe eosinophilic asthma (SEA) through its effects on eosinophil maturation, survival, and recruitment to the airways. Benralizumab is an anti-IL-5 receptor α (IL-5Rα) monoclonal antibody that binds to IL-5R on eosinophils. Binding of benralizumab to IL-5R blocks IL-5 binding and leads to eosinophil cell death via natural killer cell-mediated antibody-dependent cellular cytotoxicity, macrophage-mediated antibody-dependent cellular phagocytosis/efferocytosis, and tumour necrosis factor receptor 1-mediated apoptosis; the result is the removal of eosinophils from blood and tissue. Benralizumab was approved for the treatment of SEA in 2017 based on the WINDWARD clinical trial programme, which included the pivotal phase 3 trials SIROCCO and CALIMA. Subsequent clinical studies, as well as real-world evidence studies, have reinforced the efficacy of benralizumab for the treatment of SEA and provided evidence about its safety and tolerability profile, including in children. Clinical data have also demonstrated that reduction of background medications, such as oral and inhaled corticosteroids, is possible in patients with SEA controlled with benralizumab. Benralizumab has been investigated for the treatment of other eosinophil-associated diseases, including a phase 3 study for eosinophilic granulomatosis with polyangiitis (EGPA) in which benralizumab was non-inferior to the anti-IL-5 monoclonal antibody mepolizumab: as a result, benralizumab was recently approved for the treatment of EGPA. Phase 3 studies are ongoing with benralizumab for the treatment of hypereosinophilic syndrome and chronic obstructive pulmonary disease.

大多数严重哮喘患者有嗜酸性粒细胞表型。白细胞介素-5 （IL-5）通过影响嗜酸性粒细胞的成熟、存活和向气道募集，在严重嗜酸性粒细胞哮喘（SEA）的病理生理中起关键作用。Benralizumab是一种抗il -5受体α (IL-5Rα)单克隆抗体，可与嗜酸性粒细胞上的IL-5R结合。benralizumab与IL-5R结合阻断IL-5结合，通过自然杀伤细胞介导的抗体依赖性细胞毒性、巨噬细胞介导的抗体依赖性细胞吞噬/efferocytosis和肿瘤坏死因子受体1介导的凋亡导致嗜酸性细胞死亡；其结果是从血液和组织中去除嗜酸性粒细胞。2017年，基于WINDWARD临床试验计划，Benralizumab被批准用于治疗SEA，其中包括关键的3期试验SIROCCO和CALIMA。随后的临床研究，以及真实世界的证据研究，已经加强了benralizumab治疗SEA的有效性，并提供了关于其安全性和耐受性的证据，包括在儿童中。临床数据也表明，在使用benralizumab控制的SEA患者中，减少背景药物（如口服和吸入皮质类固醇）是可能的。Benralizumab已被研究用于治疗其他嗜酸性粒细胞相关疾病，包括一项治疗嗜酸性粒细胞肉芽肿病伴多血管炎（EGPA）的3期研究，其中Benralizumab不劣于抗il- 5单克隆抗体mepolizumab：因此，Benralizumab最近被批准用于治疗EGPA。benralizumab治疗嗜酸性粒细胞增多综合征和慢性阻塞性肺疾病的3期研究正在进行中。

{"title":"Benralizumab: Bringing winds of change to eosinophil-associated diseases","authors":"Stephanie Korn MD, PhD , Eugene R. Bleecker MD , Arnaud Bourdin MD, PhD , Christopher McCrae PhD , Maria L. Jison MD , Andrew Menzies-Gow PhD, FRCP","doi":"10.1016/j.waojou.2025.101153","DOIUrl":"10.1016/j.waojou.2025.101153","url":null,"abstract":"<div><div>The majority of patients with severe asthma have an eosinophilic phenotype. Interleukin-5 (IL-5) plays a key role in the pathophysiology of severe eosinophilic asthma (SEA) through its effects on eosinophil maturation, survival, and recruitment to the airways. Benralizumab is an anti-IL-5 receptor α (IL-5Rα) monoclonal antibody that binds to IL-5R on eosinophils. Binding of benralizumab to IL-5R blocks IL-5 binding and leads to eosinophil cell death via natural killer cell-mediated antibody-dependent cellular cytotoxicity, macrophage-mediated antibody-dependent cellular phagocytosis/efferocytosis, and tumour necrosis factor receptor 1-mediated apoptosis; the result is the removal of eosinophils from blood and tissue. Benralizumab was approved for the treatment of SEA in 2017 based on the WINDWARD clinical trial programme, which included the pivotal phase 3 trials SIROCCO and CALIMA. Subsequent clinical studies, as well as real-world evidence studies, have reinforced the efficacy of benralizumab for the treatment of SEA and provided evidence about its safety and tolerability profile, including in children. Clinical data have also demonstrated that reduction of background medications, such as oral and inhaled corticosteroids, is possible in patients with SEA controlled with benralizumab. Benralizumab has been investigated for the treatment of other eosinophil-associated diseases, including a phase 3 study for eosinophilic granulomatosis with polyangiitis (EGPA) in which benralizumab was non-inferior to the anti-IL-5 monoclonal antibody mepolizumab: as a result, benralizumab was recently approved for the treatment of EGPA. Phase 3 studies are ongoing with benralizumab for the treatment of hypereosinophilic syndrome and chronic obstructive pulmonary disease.</div></div>","PeriodicalId":54295,"journal":{"name":"World Allergy Organization Journal","volume":"18 12","pages":"Article 101153"},"PeriodicalIF":4.3,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145736987","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Identification of diagnostic genes and drug prediction of allergic asthma by integrated bioinformatics analysis, machine learning, and molecular docking 基于生物信息学分析、机器学习和分子对接的变应性哮喘诊断基因鉴定和药物预测

IF 4.3 2区医学 Q2 ALLERGY

World Allergy Organization Journal

Pub Date : 2025-12-01 DOI: 10.1016/j.waojou.2025.101147

Heng Wang MSc , Ruoyan Wang MS , Jie Lan PhD , Wanfeng Zhang PhD , Guang Li MD , Hui Nie MD , Longke Ran PhD

Background

Allergic asthma is a heterogeneous inflammatory airway disease with limited biomarkers and unclear immune mechanisms, complicating diagnosis and treatment.

Objectives

This study aimed to identify key genes in allergic asthma patients, assess their role in immune regulation, and screen for potential therapeutic agents.

Methods

RNA was extracted from blood samples of 36 allergic asthma patients and 19 healthy controls for high-throughput sequencing. Differentially Expressed Genes (DEGs) were identified and subjected to Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) enrichment analyses. Four key genes were identified by intersecting DEGs with key modular genes from Weighted Gene Co-expression Network Analysis (WGCNA), top-ranked genes from Random Forest (RF), and significant genes from Extreme Gradient Boosting (XGBoost). Core genes were determined via Protein-protein Interaction (PPI) network analysis and further evaluated using immune infiltration and molecular docking.

Results

A total of 333 DEGs were identified, mainly involved in oxygen transport and pathology. TMIGD2, OBSCN, FCGBP, and FBLN2 were screened as key genes, with OBSCN and FBLN2 designated as core genes. Immune infiltration analysis revealed associations between core genes and various immune cells, and molecular docking showed strong binding affinities of midecamycin and paricalcitol to core genes.

Conclusions

This study highlights the roles of OBSCN and FBLN2 in immune regulation in allergic asthma, suggesting midecamycin and paricalcitol as potential therapeutic agents.

背景变应性哮喘是一种异质性炎症性气道疾病，生物标志物有限，免疫机制不明确，诊断和治疗复杂。目的确定过敏性哮喘患者的关键基因，评估其在免疫调节中的作用，筛选潜在的治疗药物。方法从36例变应性哮喘患者和19例健康对照者的血样中提取srna，进行高通量测序。对差异表达基因（DEGs）进行鉴定，并进行基因本体（GO）和京都基因与基因组百科全书（KEGG）富集分析。通过与加权基因共表达网络分析（Weighted Gene Co-expression Network Analysis， WGCNA）中的关键模块基因、随机森林（Random Forest， RF）中的顶级基因和极端梯度增强（Extreme Gradient boost, XGBoost）中的重要基因的交叉deg鉴定出4个关键基因。通过蛋白相互作用（PPI）网络分析确定核心基因，并通过免疫浸润和分子对接进一步评估。结果共鉴定出333个基因，主要与氧转运和病理有关。筛选出TMIGD2、obcn、FCGBP和FBLN2为关键基因，其中obcn和FBLN2为核心基因。免疫浸润分析显示核心基因与多种免疫细胞存在关联，分子对接显示midecamycin和paricalcitol与核心基因具有较强的结合亲和力。结论本研究强调了bln和FBLN2在变应性哮喘免疫调节中的作用，提示midecamycin和paricalcitol是潜在的治疗药物。

{"title":"Identification of diagnostic genes and drug prediction of allergic asthma by integrated bioinformatics analysis, machine learning, and molecular docking","authors":"Heng Wang MSc , Ruoyan Wang MS , Jie Lan PhD , Wanfeng Zhang PhD , Guang Li MD , Hui Nie MD , Longke Ran PhD","doi":"10.1016/j.waojou.2025.101147","DOIUrl":"10.1016/j.waojou.2025.101147","url":null,"abstract":"<div><h3>Background</h3><div>Allergic asthma is a heterogeneous inflammatory airway disease with limited biomarkers and unclear immune mechanisms, complicating diagnosis and treatment.</div></div><div><h3>Objectives</h3><div>This study aimed to identify key genes in allergic asthma patients, assess their role in immune regulation, and screen for potential therapeutic agents.</div></div><div><h3>Methods</h3><div>RNA was extracted from blood samples of 36 allergic asthma patients and 19 healthy controls for high-throughput sequencing. Differentially Expressed Genes (DEGs) were identified and subjected to Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) enrichment analyses. Four key genes were identified by intersecting DEGs with key modular genes from Weighted Gene Co-expression Network Analysis (WGCNA), top-ranked genes from Random Forest (RF), and significant genes from Extreme Gradient Boosting (XGBoost). Core genes were determined via Protein-protein Interaction (PPI) network analysis and further evaluated using immune infiltration and molecular docking.</div></div><div><h3>Results</h3><div>A total of 333 DEGs were identified, mainly involved in oxygen transport and pathology. TMIGD2, OBSCN, FCGBP, and FBLN2 were screened as key genes, with OBSCN and FBLN2 designated as core genes. Immune infiltration analysis revealed associations between core genes and various immune cells, and molecular docking showed strong binding affinities of midecamycin and paricalcitol to core genes.</div></div><div><h3>Conclusions</h3><div>This study highlights the roles of OBSCN and FBLN2 in immune regulation in allergic asthma, suggesting midecamycin and paricalcitol as potential therapeutic agents.</div></div>","PeriodicalId":54295,"journal":{"name":"World Allergy Organization Journal","volume":"18 12","pages":"Article 101147"},"PeriodicalIF":4.3,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145736989","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Comments on “Clinical-cytological grading: An integrated approach to stratifying CRSwNP beyond eosinophilia” 《临床-细胞学分级：一种除嗜酸性粒细胞外的CRSwNP分层的综合方法》评论

IF 4.3 2区医学 Q2 ALLERGY

World Allergy Organization Journal

Pub Date : 2025-12-01 DOI: 10.1016/j.waojou.2025.101143

Matteo Gelardi MD

引用次数: 0

Messenger RNA vaccines in the prevention of allergic diseases 信使RNA疫苗在预防过敏性疾病中的作用

IF 4.3 2区医学 Q2 ALLERGY

World Allergy Organization Journal

Pub Date : 2025-12-01 DOI: 10.1016/j.waojou.2025.101150

Song Li MD , Yiwu Zheng PhD , Lei Cheng MD, PhD

Messenger RNA (mRNA) vaccines are composed of mRNA sequences encoding pathogens. The first coronavirus mRNA vaccine (BNT162B2, Pfizer/BioNTech), approved in the United Kingdom in 2020, had prevented approximately 20 million deaths globally within the first year of use. mRNA vaccines were initially used against tumors and infectious diseases, but recent research has also turned its attention to the prevention of allergic diseases. Here, we summarized the characteristics and outcomes of mRNA vaccines in preventing allergic diseases and analyzed their advantages over traditional inactivated vaccines and DNA vaccines. This review focused on the feasibility, potential mechanisms, and preclinical research results of prophylactic allergen mRNA vaccines in the prevention of type I hypersensitivity reactions, and preliminarily addressed the key issues in clinical trials of allergen mRNA vaccines. Allergen mRNA vaccines hold promise for preventing IgE-mediated allergic diseases, yet their potential uses warrant further clinical investigations.

信使RNA （mRNA）疫苗由编码病原体的mRNA序列组成。首个冠状病毒mRNA疫苗（BNT162B2，辉瑞/BioNTech）于2020年在英国获得批准，在使用的第一年，在全球预防了约2000万人死亡。mRNA疫苗最初用于治疗肿瘤和传染病，但最近的研究也将注意力转向了预防过敏性疾病。本文综述了mRNA疫苗预防过敏性疾病的特点和效果，并分析了mRNA疫苗相对于传统灭活疫苗和DNA疫苗的优势。本文综述了预防性变应原mRNA疫苗预防I型超敏反应的可行性、潜在机制和临床前研究结果，并初步探讨了变应原mRNA疫苗临床试验中的关键问题。过敏原mRNA疫苗有望预防ige介导的过敏性疾病，但其潜在用途需要进一步的临床研究。

引用次数: 0

Global prevalence of eligibility for biologic therapy in ATS/ERS-defined severe asthma: A systematic review ATS/ ers定义的严重哮喘生物治疗的全球患病率：一项系统综述

IF 4.3 2区医学 Q2 ALLERGY

World Allergy Organization Journal

Pub Date : 2025-12-01 DOI: 10.1016/j.waojou.2025.101155

Freda Yang MBChB MD(Res) , Justin D. Salciccioli MBBS MA , Rhea E. Patel BSc , Marcus McClean MBChB , Chloe I. Bloom MBBS PhD

Background

Biologic therapies improve outcomes in severe asthma, but eligibility criteria vary globally, influencing the proportion of patients who qualify. We systematically reviewed studies to estimate the global prevalence of biologic eligibility in patients aged ≥12 years with American Thoracic Society / European Respiratory Society (ATS/ERS)-defined severe asthma and the proportion eligible for each biologic.

Methods

Following PRISMA guidelines (PROSPERO CRD42023393897), we searched MEDLINE, EMBASE, Web of Science, and ClinicalTrials.gov for studies published between 2000 and 2025 that reported the proportion of biologic-naïve, severe asthma patients eligible for omalizumab, mepolizumab, benralizumab, reslizumab, dupilumab, or tezepelumab. Two reviewers independently screened studies, extracted data on eligibility proportions and criteria, and assessed quality using the AXIS tool.

Results

Ten observational studies, including 3500 patients with ATS/ERS-defined severe asthma, met the inclusion criteria. Across all studies, 1770 patients (51%) were eligible for at least 1 biologic, though estimates ranged widely from 24% to 91%, largely reflecting differences in national eligibility criteria. Omalizumab eligibility was reported in 8 studies (16%, range 6%–66%), mepolizumab in 9 studies (27%, 19%–78%), benralizumab in 6 studies (25%, 19%–53%), reslizumab in 6 studies (17%, 6%–41%), and dupilumab in 2 studies (41%, 37%–75%). No study assessed tezepelumab. Overall, the lowest eligibility (24%) was reported in the European IDEAL cohort due to stringent exacerbation and biomarker criteria, whereas the highest (91%) was observed in a Canadian single-centre cohort using less restrictive national regulatory criteria.

Conclusion

Globally, approximately 51% of adults with severe asthma are eligible for biologic therapy, excluding tezepelumab. Among available biologics, eligibility is generally higher for anti-IL5/IL5Rα therapies than for anti-IgE, and appears highest for anti-IL4Rα, although data for the latter remain limited.

生物疗法改善了严重哮喘的预后，但全球范围内的资格标准不同，影响了符合条件的患者比例。我们系统地回顾了研究，以估计≥12岁美国胸科学会/欧洲呼吸学会（ATS/ERS）定义的严重哮喘患者中生物制剂的全球患病率以及每种生物制剂的适用比例。方法：按照PRISMA指南（PROSPERO CRD42023393897），我们检索MEDLINE、EMBASE、Web of Science和ClinicalTrials.gov，检索2000年至2025年间发表的研究，这些研究报告了biologic-naïve、重度哮喘患者中适合使用omalizumab、mepolizumab、benralizumab、reslizumab、dupilumab或tezepelumab的比例。两位审稿人独立筛选研究，提取有关合格比例和标准的数据，并使用AXIS工具评估质量。结果10项观察性研究，包括3500例ATS/ ers定义的严重哮喘患者，符合纳入标准。在所有研究中，1770名患者（51%）符合至少1种生物制剂的治疗条件，尽管估计范围从24%到91%不等，这在很大程度上反映了各国入选标准的差异。8项研究报告了Omalizumab的适格性（16%，范围6%-66%），9项研究报告了mepolizumab(27%, 19%-78%)， 6项研究报告了benralizumab(25%, 19%-53%)， 6项研究报告了reslizumab(17%, 6%-41%)， 2项研究报告了dupilumab（41%, 37%-75%）。没有研究评估tezepelumab。总体而言，由于严格的恶化和生物标志物标准，欧洲IDEAL队列的适格率最低（24%），而加拿大单中心队列的适格率最高（91%），使用较少限制的国家监管标准。在全球范围内，大约51%的成人严重哮喘患者有资格接受生物治疗，不包括tezepelumab。在现有的生物制剂中，抗il5 /IL5Rα治疗的适格性通常高于抗ige治疗，而抗il4r α治疗的适格性最高，尽管后者的数据仍然有限。

{"title":"Global prevalence of eligibility for biologic therapy in ATS/ERS-defined severe asthma: A systematic review","authors":"Freda Yang MBChB MD(Res) , Justin D. Salciccioli MBBS MA , Rhea E. Patel BSc , Marcus McClean MBChB , Chloe I. Bloom MBBS PhD","doi":"10.1016/j.waojou.2025.101155","DOIUrl":"10.1016/j.waojou.2025.101155","url":null,"abstract":"<div><h3>Background</h3><div>Biologic therapies improve outcomes in severe asthma, but eligibility criteria vary globally, influencing the proportion of patients who qualify. We systematically reviewed studies to estimate the global prevalence of biologic eligibility in patients aged ≥12 years with American Thoracic Society / European Respiratory Society (ATS/ERS)-defined severe asthma and the proportion eligible for each biologic.</div></div><div><h3>Methods</h3><div>Following PRISMA guidelines (PROSPERO CRD42023393897), we searched MEDLINE, EMBASE, Web of Science, and ClinicalTrials.gov for studies published between 2000 and 2025 that reported the proportion of biologic-naïve, severe asthma patients eligible for omalizumab, mepolizumab, benralizumab, reslizumab, dupilumab, or tezepelumab. Two reviewers independently screened studies, extracted data on eligibility proportions and criteria, and assessed quality using the AXIS tool.</div></div><div><h3>Results</h3><div>Ten observational studies, including 3500 patients with ATS/ERS-defined severe asthma, met the inclusion criteria. Across all studies, 1770 patients (51%) were eligible for at least 1 biologic, though estimates ranged widely from 24% to 91%, largely reflecting differences in national eligibility criteria. Omalizumab eligibility was reported in 8 studies (16%, range 6%–66%), mepolizumab in 9 studies (27%, 19%–78%), benralizumab in 6 studies (25%, 19%–53%), reslizumab in 6 studies (17%, 6%–41%), and dupilumab in 2 studies (41%, 37%–75%). No study assessed tezepelumab. Overall, the lowest eligibility (24%) was reported in the European IDEAL cohort due to stringent exacerbation and biomarker criteria, whereas the highest (91%) was observed in a Canadian single-centre cohort using less restrictive national regulatory criteria.</div></div><div><h3>Conclusion</h3><div>Globally, approximately 51% of adults with severe asthma are eligible for biologic therapy, excluding tezepelumab. Among available biologics, eligibility is generally higher for anti-IL5/IL5Rα therapies than for anti-IgE, and appears highest for anti-IL4Rα, although data for the latter remain limited.</div></div>","PeriodicalId":54295,"journal":{"name":"World Allergy Organization Journal","volume":"18 12","pages":"Article 101155"},"PeriodicalIF":4.3,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145736985","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Epidemiology and allergen sensitisation in patients undergoing prick testing 接受点刺试验患者的流行病学和过敏原致敏

IF 4.3 2区医学 Q2 ALLERGY

World Allergy Organization Journal

Pub Date : 2025-12-01 DOI: 10.1016/j.waojou.2025.101133

Olga Patricia Monge Ortega MD, MSc , Ignacio Rivero Gairaud MD , Giovanni Sedó Mejía MD

Background

Epidemiological data on allergen sensitisation in Costa Rica are limited, while prevalence of allergic diseases in the world is rising. This study aims to determine the epidemiology and patterns of allergen sensitisation in patients who underwent prick testing.

Methods

A retrospective descriptive-observational study was conducted, including 1001 patients aged >12 years undergoing prick testing between 2019 and 2021. Descriptive statistics were used to collect data on demographics, aeroallergens and food sensitisation.

Results

The study population had a mean age of 35.9 ± 16.3 years and was predominantly female. Most patients were from San José, with chronic rhinitis being the most common pre-test diagnosis. Mites (Dermatophagoides farinae, Dermatophagoides pteronissinus), feline epithelium and cockroach mixture were the most common aeroallergens, while shrimp and shellfish were the main food allergens. A significant increase in sensitisation was observed in patients with pre-existing allergic conditions.

Conclusion

The results underline the high prevalence of allergen sensitisation in patients with allergic diseases in Costa Rica, especially in urban areas, and highlight the importance of allergen identification for effective management and prevention.

背景：哥斯达黎加关于过敏原致敏的流行病学数据有限，而世界上过敏性疾病的患病率正在上升。本研究旨在确定接受点刺试验的患者中过敏原致敏的流行病学和模式。方法采用回顾性描述性观察性研究，纳入1001例12岁患者，于2019 - 2021年接受针刺试验。描述性统计用于收集人口统计、空气过敏原和食物致敏的数据。结果研究人群平均年龄为35.9±16.3岁，以女性为主。大多数患者来自圣何塞，慢性鼻炎是最常见的检测前诊断。螨类（Dermatophagoides farinae, Dermatophagoides pteronissinus）、猫上皮和蟑螂混合物是最常见的空气过敏原，虾类和贝类是主要的食物过敏原。在已有过敏条件的患者中观察到致敏性显著增加。结论哥斯达黎加变应性疾病患者中过敏原致敏率较高，尤其是在城市地区，同时强调了过敏原识别对有效管理和预防的重要性。

{"title":"Epidemiology and allergen sensitisation in patients undergoing prick testing","authors":"Olga Patricia Monge Ortega MD, MSc , Ignacio Rivero Gairaud MD , Giovanni Sedó Mejía MD","doi":"10.1016/j.waojou.2025.101133","DOIUrl":"10.1016/j.waojou.2025.101133","url":null,"abstract":"<div><h3>Background</h3><div>Epidemiological data on allergen sensitisation in Costa Rica are limited, while prevalence of allergic diseases in the world is rising. This study aims to determine the epidemiology and patterns of allergen sensitisation in patients who underwent prick testing.</div></div><div><h3>Methods</h3><div>A retrospective descriptive-observational study was conducted, including 1001 patients aged >12 years undergoing prick testing between 2019 and 2021. Descriptive statistics were used to collect data on demographics, aeroallergens and food sensitisation.</div></div><div><h3>Results</h3><div>The study population had a mean age of 35.9 ± 16.3 years and was predominantly female. Most patients were from San José, with chronic rhinitis being the most common pre-test diagnosis. Mites (<em>Dermatophagoides farinae</em>, <em>Dermatophagoides pteronissinus</em>), feline epithelium and cockroach mixture were the most common aeroallergens, while shrimp and shellfish were the main food allergens. A significant increase in sensitisation was observed in patients with pre-existing allergic conditions.</div></div><div><h3>Conclusion</h3><div>The results underline the high prevalence of allergen sensitisation in patients with allergic diseases in Costa Rica, especially in urban areas, and highlight the importance of allergen identification for effective management and prevention.</div></div>","PeriodicalId":54295,"journal":{"name":"World Allergy Organization Journal","volume":"18 12","pages":"Article 101133"},"PeriodicalIF":4.3,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145737519","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0